一种基于聚乙烯 (ε-Caprolactone) 的新型光交联液态共聚物作为多功能药物输送平台
Marcus Flowers1, Nicole Mertens1, Amanda Billups1
1Department of Biomedical Engineering, University of Minnesota, 7-105 Hasselmo Hall, 312 Church Street S.E, Minneapolis, MN 55455, USA.
Pharmaceutics
|November 27, 2024
概括
一种新的液态共聚物,mPA20,提供了多功能药物输送. 这种可生物降解的聚合物可以注射或交叉连接,使得持续释放和细胞内输送的疏水性药物没有观察到细胞毒性.
科学领域:
- 生物材料科学 生物材料科学
- 聚合物化学 聚合物化学
- 药物输送系统 药物输送系统
背景情况:
- 疏水生物降解聚合物是持续释放药物的有效注射矩阵.
- 基于聚乙烯 (PCL) 的液态共聚物为药物输送提供了独特的优势.
研究的目的:
- 设计,合成和描述基于PCL的新型低化液态共聚合物.
- 为了确定这种共聚合物的实用性,作为一个多功能药物输送平台.
主要方法:
- 合成了一种新型的共聚合物 (mPA20),由短PCL块组成,通过一种一反应,通过酸-性乙链接连接在一起.
- 描述了共聚合物的特性,包括可注射性,pH敏感降解和光交联能力.
- 评估了尼罗河红色 (NR) 的持续释放和细胞内输送,使用mPA20作为液体储存,固体矩阵,纳米滴和纳米凝.
主要成果:
- mPA20是在生理温度下具有pH敏感降解的无形,可注射液体.
- 甲基酸终结的mPA20可以通过光交叉连接到具有可调整机械性能的固体矩阵中.
- 尼罗河红色的持续释放和有效的细胞内输送是通过使用mPA20在各种配方 (液体储存,固体矩阵,纳米凝) 实现的,没有细胞毒性.
结论:
- mPA20是一种高度适应的疏水性液体共聚物,用于受控释放和细胞内输送.
- 它的可光交叉链接性和pH敏感降解性使其适用于可注射或可植入的仓库和纳米级载体.
- 这种新型材料显示出提供难溶性药物的巨大潜力.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
139
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
139
01:27Drug Delivery Systems: Different Types
420
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
420
01:19Modified-Release Drug Delivery Systems: Overview
243
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
243
01:23Modified-Release Drug Delivery Systems: Classification
320
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
320
01:24Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
167
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
167